| Autor: |
Ziad Hijazi, John H Alexander, Christopher B Granger, Agneta Siegbahn, Lars Wallentin, Raffaele De Caterina, Bernard J Gersh, Elaine M Hylek, Michael D Ezekowitz, Tymon Pol, Johan Lindbäck, M Cecilia Bahit, JW Eikelboom, Renato Lopes |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Open Heart, Vol 8, Iss 1 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2053-3624 |
| DOI: |
10.1136/openhrt-2020-001471 |
| Popis: |
Objectives Growth differentiation factor 15 (GDF-15) is a biomarker independently associated with bleeding and death in anticoagulated patients with atrial fibrillation (AF). GDF-15 is also used as one component in the more precise biomarker-based ABC (age, biomarkers, clinical history)-AF-bleeding and ABC-AF-death risk scores. Data from large trials indicate a geographic variability in regard to overall outcomes, including bleeding and mortality risk. Our aim was to assess the consistency of the association between GDF-15, ABC-AF-bleeding score and ABC-AF-death score, with major bleeding and death, across world geographic regions.Methods Data were available from 14 767 patients with AF from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial and 8651 patients with AF from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial in this cohort study. GDF-15 was analysed from plasma samples obtained at randomisation. The geographical consistency of the associations between outcomes and GDF-15, ABC-AF-bleeding score and ABC-AF-death scores were assessed by Cox-regression models including interactions with predefined geographical region.Results GDF-15 and the ABC-AF-bleeding score were associated with major bleeding in both trials across regions (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
